Centrioles are critical for many cellular processes including cell division and cilia assembly. The number of centrioles within a cell is under strict control, and deregulation of centriole copy number is a hallmark of cancer. The molecular mechanisms that halt centriole amplification have not been fully elucidated. Here, we found that centrosomal protein of 76 kDa (Cep76), previously shown to restrain centriole amplification, interacts with cyclin-dependent kinase 2 (CDK2) and is a bona fide substrate of this kinase. Cep76 is preferentially phosphorylated by cyclin A/CDK2 at a single site S83, and this event is crucial to suppress centriole amplification in S phase. A novel Cep76 mutation S83C identified in a cancer patient fails to prevent centriole amplification. Mechanistically, Cep76 phosphorylation inhibits activation of polo-like kinase 1 (Plk1), thereby blocking premature centriole disengagement and subsequent amplification. Cep76 can also be acetylated, and enforced acetylation at K279 dampens the protein's ability to inhibit amplification and precludes S83 phosphorylation. Acetylation of Cep76 normally occurs in G2 phase and correlates with loss of protein function. Our data suggest that temporal changes in post-translational modifications of Cep76 during the cell cycle regulate its capacity to suppress centriole amplification, and its deregulation may contribute to malignancy.
INTRODUCTION
Centrosomes are well-known for their role in cell division. 1 They are composed of a pair of centrioles surrounded by a pericentriolar matrix from which microtubules emanate and elongate. A single centrosome present in G1 phase of the cell cycle undergoes duplication in S phase. The duplicated centrosomes, once separated, establish the mitotic spindle at the onset of mitosis, ensuring faithful segregation of chromosomes into daughter cells. Centrosome duplication, like DNA replication, occurs once and only once per cell cycle and is under stringent control. 2 Too few or too many centrosomes could jeopardize cell division, leading to cancer development. 3 Indeed, centrosome amplification has been documented in many types of cancers [4] [5] [6] and is thought to be an important contributor to malignant transformation 5, [7] [8] [9] owing to its capacity to induce chromosome mis-segregation and cell invasion. 10, 11 It is therefore of paramount importance to decipher the poorly understood mechanisms governing the fidelity of centrosome duplication.
Cyclin-dependent kinase 2 (CDK2) is a critical regulator of the cell cycle associated with cancer development. Although CDK2 is dispensable for viability in mice 12, 13 and its loss can be compensated by CDK1, 14 chemical genetics reveals a requirement of this kinase in cell cycle progression and cell proliferation. 15 CDK2 also regulates centrosome duplication [16] [17] [18] [19] by phosphorylating several key centrosomal substrates. Centrosome duplication begins when nucleophosmin/B23, a protein that associates with unduplicated centrosomes, dissociates from this organelle upon CDK2 phosphorylation. 20 CDK2 phosphorylates Mps1 and CP110, two centrosomal proteins essential for duplication and amplification. 21, 22 Furthermore, CDK2 cooperates with polo-like kinase 4 to regulate centrosome amplification, although the two proteins do not appear to interact. 23, 24 Elegant studies using knockout mouse embryonic fibroblasts have demonstrated that although CDK2 is not required for normal centrosome duplication, it is needed for amplification. 25, 26 Thus, current evidence favors the notion that CDK2 activity supports centrosome duplication/ amplification. It is not entirely clear if CDK2 substrates always exert a positive effect on duplication/amplification, as a complete set of centrosomal CDK2 substrates have not been identified. 27 Centrosomal protein of 76 kDa (Cep76) was originally identified as a novel component of the centrosome using mass spectrometry-based proteomics. 28 Previous studies indicate that this protein has a pivotal role in restraining centriole amplification. 29 A loss of Cep76 induces accumulation of supernumerary centrioles primarily during S phase. 29 In addition, ectopic expression of Cep76 specifically suppresses centriole and centrosome amplification induced by hydroxyurea (HU), a drug that inhibits S phase progression and promotes multiple rounds of centriole duplication. 29, 30 Interestingly, Cep76 protein levels peak in S phase, 29 coinciding with elevated CDK2 activity and centriole duplication. 31 The relationship between Cep76 and CDK2, if any, is unknown. Moreover, precisely how Cep76 suppresses centriole amplification at a mechanistic level has not been characterized.
RESULTS

Cep76 preferentially interacts with cyclin A/CDK2
In an effort to identify potential upstream and downstream regulators of Cep76, we performed a proteomic screen for components of Cep76-containing complexes. Two centrosomal proteins, CP110 and Cep97, previously shown to interact with Cep76 were found, 29 confirming the success of the screen. In addition, we identified CDK2, an S/G2 phase CDK, 32, 33 as a novel Cep76-interacting partner from two independent experiments. To determine whether Cep76 and CDK2 interact in cells, we transfected a plasmid expressing HA-CDK2 in HEK293 cells, performed immunoprecipitations with anti-HA antibody, and showed that both HA-CDK2 and endogenous Cep76 were co-precipitated ( Figure 1a ). When Flag-Cep76 was expressed, endogenous CDK2 was similarly detected in Flag-Cep76 immunoprecipitates (Figure 1b ). Flag-Cep76 specifically associated with CDK2 but not with other CDKs, including CDK1, CDK4 and CDK6, involved in cell cycle progression ( Figure 1b ). CDK2 is known to pair with cyclin E in late G1 and cyclin A in S/G2 phase, 32 and we found that Flag-Cep76 interacts with cyclin A only ( Figure 1b ). The interaction between Cep76 and cyclin A was confirmed in other cell lines including U2OS and Saos-2 ( Figure 1c and data not shown). Endogenous Cep76, cyclin A and CDK2 also interacted with each other (Figure 1d ). Furthermore, in vitro binding experiments using purified proteins revealed that while Cep76 associates weakly with cyclin E/CDK2, it binds strongly to cyclin A/CDK2 (Figure 1e ), in close agreement with our immunoprecipitation results ( Figure 1b ). Taken together, these findings suggest that Cep76 preferentially interacts with cyclin A/ CDK2.
Cep76 is phosphorylated by cyclin A/CDK2 at a single site S83 Cyclin/CDKs are known to phosphorylate substrates possessing the consensus sequence (S/T)-P. [34] [35] [36] Sequence analysis of Cep76 revealed the presence of four putative consensus phosphorylation sites (Figure 2a ). To determine whether Cep76 is a cyclin/CDK substrate, we first immunoprecipitated Flag-Cep76 from HEK293 cells, excised the band corresponding to the recombinant protein from a sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and analyzed phosphorylation by mass spectrometry. In three independent experiments, we reproducibly detected phosphorylation of one single-amino acid, serine 83 (S83) (Figure 2b ), which overlaps with one of the four predicted CDK consensus sites of Cep76 (Figure 2a ). Phosphorylation on S83 can be attenuated by the addition of a CDK inhibitor roscovitine (Supplementary Figure S1 ), indicating that Cep76 is phosphorylated by CDK in vivo. Next, we performed in vitro kinase assays using purified cyclin/CDK and Cep76 and asked if the former directly phosphorylates the latter. In accordance with earlier results that Cep76 strongly interacts with cyclin A/CDK2, this protein is robustly phosphorylated by cyclin A/CDK2 (Figure 2c ). Cyclin E/CDK2, on the other hand, exhibited negligible kinase activity on Cep76 (Figure 2c ). In comparison, a known cyclin/CDK substrate histone H1 and a non-substrate NPHP5 are good and poor substrate for both kinases, respectively ( Figure 2c ). Moreover, we generated two Cep76 phosphorylation site mutants, one in which S83 was mutated to alanine (S83A) and the other in which all four putative CDK consensus sites were mutated to alanine (S83AT3335A-S558AS615A; quadruple mutant), and tested their ability to undergo cyclin A/CDK2-dependent phosphorylation. We found that phosphorylation of S83A was drastically reduced compared with wild-type protein, and the extent of diminution was comparable to the quadruple mutant ( Figure 2d ). The failure of cyclin A/CDK2 to phosphorylate mutant proteins is not a consequence of impaired binding, as wild-type, S83A and the quadruple mutant bound equally well to the kinase (Figure 2e ). S83, therefore, appears to be the only CDK consensus site that becomes phosphorylated by cyclin A/CDK2. In addition to CDK consensus sites, a number of cyclin/CDK substrates possess KXL/RXL motifs known to facilitate interactions with cyclins, especially cyclin A, allowing for efficient substrate-kinase interaction and substrate phosphorylation. [37] [38] [39] Cep76 contains nine putative KXL/RXL motifs (Figure 2a and Supplementary S2A) and exhibits preferential binding to cyclin A (Figures 1b and e); thus, we sought to examine the potential role of these motifs in mediating interaction with cyclin A. We mutated each of the nine KXL/RXL motifs individually by replacing arginine and leucine with alanine (AXA mutants, Supplementary Figure S2A ), and found that these mutants are still able to interact with cyclin A (Supplementary Figure S2B) . A limited set of double and triple AXA mutants were tested and they could also bind cyclin A (data not shown). Furthermore, AXA mutant proteins appeared to be fully functional, as they localized to the centrosome and were able to suppress centriole amplification ( Supplementary Figures S2C and S3 ; see below for functional assays). From these results, we conclude that other determinants apart from the KXL/RXL motifs are likely responsible for the interaction between Cep76 and cyclin A.
Phosphorylation of Cep76 suppresses centriole amplification in S phase
To assess the functional significance of Cep76 phosphorylation, we conducted rescue experiments in which we introduced recombinant wild-type Cep76 or the S83A mutant in U2OS cells depleted of endogenous Cep76, using a small interfering RNA (siRNA) oligo that targets the 3′UTR of Cep76 mRNA. A phosphomimetic mutant S83E was also tested in the same assay. A loss of Cep76 specifically leads to the production of supernumerary centrioles in S phase, 29 and we indeed confirmed an earlier report that Cep76 depletion led to a three-to fourfold increase in the number of cells with 44 centriolar CP110 dots or 42 dots of C-Nap1, which stains the proximal ends of mother and daughter centrioles (Figures 3a and b and data not shown).
Remarkably, this phenotype was rescued by wild-type Cep76 and S83E, but not S83A mutant expression (Figures 3a and b, Supplementary Figure S4A and data not shown), despite comparable levels of protein expression ( Figure 3c ). Furthermore, both S83A and S83E mutants were properly localized to the centrosome (Figure 3b ). These data suggest that the phosphomimetic mutant is functional and that phosphorylation at S83 is critical for Cep76 to suppress centriole amplification.
In addition, we tested the ability of wild-type Cep76, S83A and S83E mutants to suppress HU-induced centriole amplification. The percentages of HU-treated control cells possessing 44 CP110 (centriolar) dots and 42 γ-tubulin (centrosomal) dots werẽ 30-35% and~35-40%, respectively. These percentages dropped to~5-15% and~10-15% in HU-treated cells expressing wild-type Cep76 or the S83E mutant (Figures 4a and b and Supplementary Figure S4B ), indicating that either protein inhibits amplification. In contrast, expression of the S83A mutant in HUarrested cells did not suppress amplification, as the percentages of cells with 44 CP110 dots and 42 γ-tubulin dots (~34 and 33%, respectively) were similar to control (Figures 4a and b ). Finally, we verified that wild-type Cep76, S83A and S83E proteins were expressed at similar levels ( Figure 4c ). Our rescue experiments and HU overduplication assay altogether revealed that phosphorylation of Cep76 at S83 prevents centriole amplification in S phase.
Significance of Cep76 phosphorylation in human cancer
As Cep76 is critical for protection against centriole amplification, a hallmark of cancer cells, a loss of protein function may cause a predisposition to cancer. A database search for somatic mutations in human cancer uncovered the Cep76 S83C mutation, identified in 1 of 307 cases of cervical squamous cell carcinoma and endocervical adenocarcinoma. It is currently unknown whether the mutation is present in one or both gene copies. The S83C mutation destroys a CDK2 phosphorylation site, and accordingly, we predicted that it would cripple protein function. Indeed, mutant S83C protein was unable to suppress centriole amplification induced by HU (Figures 5a-c) or depletion of Cep76 ( Supplementary Figures S5A and B) . 
Mechanism underlying suppression of centriole amplification by Cep76
We sought to address the mechanism by which Cep76 prevents centriole amplification. As CDK2 promotes centriole amplification [16] [17] [18] [19] and certain CDK2 substrates are known to regulate the kinase, [40] [41] [42] we first asked whether the activity of cyclin A/CDK2 is inhibited by Cep76. Cyclin A/CDK2 activity was monitored using histone H1 as a substrate in the presence of the S83A or S83E mutant, neither of which is phosphorylated by the kinase (Figure 2d ). Excessive amounts of S83A or S83E did not substantially modulate cyclin A/CDK2 kinase activity toward histone H1 (Figure 5d ), suggesting that Cep76 is not an inhibitor of cyclin A/CDK2. Next, we examined if Cep76 regulates targeting of the kinase to the centrosome and hence, its ability to phosphorylate centrosomal substrates. Although CDK2 and cyclin A were both reported to be associated with centrosomes, [43] [44] [45] [46] depletion of Cep76 slightly influenced the centrosomal amount of cyclin A and CDK2 ( Supplementary Figures S6A and B ). Thus, Cep76 has minimal effect on the abundance and activity of cyclin A/CDK2 at the centrosome. Centriole disengagement is a prerequisite for a new round of duplication 47 and reduplication induced by HU. 48 We therefore asked if Cep76 suppresses amplification by restraining centriole disengagement. Centriole disengagement was determined by examining the spacing of CP110/γ-tubulin dots and the ratio of CP110 to γ-tubulin dots. When the two centrioles are engaged, two closely spaced CP110 dots are associated with a single γ-tubulin dot and a 2:1 ratio of CP110:γ-tubulin is expected. Centriole disengagement causes centrioles to move further apart, and in this scenario, each CP110 dot is associated with a single γ-tubulin dot and a 1:1 ratio of CP110:γ-tubulin is expected. We noticed a 2:1 ratio, but rarely a 1:1 ratio, of CP110:γ-tubulin dots in HU-treated cells expressing wild-type Cep76 or S83E ( Figure 5e ). In striking contrast, a 1:1 ratio of CP110:γ-tubulin dots was frequently observed in a sub-population of HU-treated control cells or cells expressing S83A that have not undergone amplification ( Figure 5e ). In addition, we found that activated polo-like kinase 1 (Plk1) or Plk1-pT210, reportedly associated with disengaged centrioles in HU-treated control cells, 48 is present at centrioles in HU-treated cells expressing S83A only ( Figure 5f ). From these results, we conclude that Cep76 inhibits centriole disengagement and consequently amplification by blocking Plk1 activation at the centrosome.
To further interrogate the relationship between Cep76 and Plk1, we found that centriole amplification because of loss of Cep76 can be prevented by the addition of a Plk1 inhibitor BI 2536 (Supplementary Figure S7A) . Moreover, although centriole amplification is suppressed by enforced expression of Cep76 in HU-treated cells, this phenotype can be overridden by co-expression of constitutively active Plk1 (Plk1-T210D) (Supplementary Figure S7B) . Taken together, these data suggest that Cep76 inhibits Plk1 at the centrosome.
Acetylation of Cep76 at K279 cannot suppress centriole amplification So far, we have demonstrated that phosphorylation at S83 is crucial for Cep76 function in S phase. As protein function is often controlled by different types of post-translational modification, 49 we first examined if Cep76 could be regulated by other modifications. A recent proteomic study identified lysine 279 (K279) as an acetylation site on Cep76, 50 although its biological relevance is unknown. To determine if Cep76 is acetylated, we immunoprecipitated Cep76 and showed that the endogenous protein is highly acetylated when cells were treated with a histone deacetylase inhibitor trichostatin A (Figure 6a) immunoprecipitations with an anti-acetyl-lysine antibody revealed a marked increase in endogenous Cep76 acetylation upon trichostatin A treatment (Figure 6b ). Acetylation of recombinant Cep76 could also be detected ( Supplementary Figures S8A and B) . We subsequently confirmed that acetylation takes place at K279, as an acetylation site mutant in which K279 was mutated to an arginine (K279R) exhibited considerably less acetylation compared with wild-type protein (Figure 6c ). Next, we asked if acetylation impacts Cep76 function. For this purpose, the ability of the acetylmimetic mutant K279Q, along with K279R, to suppress centriole amplification was investigated. We found that centriole overduplication induced by depletion of Cep76 or prolonged HU treatment was suppressed by K279R but not K279Q expression (Figures 6d and e ). Both mutants localize to the centrosome and showed similar levels of protein expression compared with wildtype protein (Figure 6f and data not shown). Thus, Cep76 can be acetylated at K279, and acetylation likely dampens the protein's capacity to suppress centriole amplification.
To gain molecular insight into why the K279R but not the K279Q mutant is proficient in suppressing centriole amplification and to explore the possibility of post-translational modification crosstalk, we determined whether these mutant proteins could be phosphorylated by cyclin A/CDK2 in vitro. In sharp contrast to K279Q, the K279R mutant was robustly phosphorylated, reaching a level comparable to wild-type protein (Figure 6g ). Importantly, phosphorylation of K279R appears to occur on S83, as the S83AK279R double mutant exhibited markedly reduced phosphorylation (Figure 6g ). The functionality of the K279R mutant is similarly dependent on S83, as the S83AK279R mutant could no longer suppress HU-induced amplification (Figures 6e and f) .
Remarkably, we found that the S83EK279Q double mutant, similar to the K279Q single mutant, was also unable to suppress centriole amplification induced by HU (Figures 6e and f) , indicating that K279 acetylation alone is sufficient to override the effect of S83 phosphorylation and turn off Cep76. Considered together, our data suggest that acetylation at K279 negatively regulates Cep76 by limiting protein activity and S83 phosphorylation.
Temporal changes in Cep76 post-translational modifications correlate with protein function Next, we examined when phosphorylation and acetylation of Cep76 occur in the cell cycle. For analysis of protein phosphorylation, the abundance of S83 phosphopeptide was quantitatively determined by mass spectrometric analysis of Cep76 protein immunopurified from synchronized cells. These experiments revealed that S83 phosphorylation increases from G1 to S but decreases thereafter (Figure 7a) . Similarly, when we immunoprecipitated Flag-Cep76 from synchronized cells and western blotted the resulting immunoprecipitates with anti-phosphoserine antibody, we found that phosphorylation is highly enriched in S phase (Supplementary Figure S9) . Thus, S83 phosphorylation appears to coincide with Cep76 function during S phase. For analysis of protein acetylation, we expressed Flag-Cep76 in synchronized cells and showed that the protein is more highly acetylated in G2 compared with other cell cycle phases (Figure 7b ). Fittingly, Cep76 failed to inhibit centriole amplification induced by RO 3306 (Figures 7c-e ), a small molecule inhibitor that triggers prolonged arrest in G2 phase and repeated rounds of centriole duplication. 48, 51, 52 In these cells, both centriole disengagement and centrosomal Plk1-pT210 staining were observed (Figures 7f  and g) . As a further proof that acetylation of Cep76 in G2 phase leads to a loss of protein function, we found that Cep76 could not prevent centriole amplification induced by doxorubicin (Figure 7h ), a radiomimetic drug that induces G2 arrest. 52 Our findings suggest that acetylation of Cep76 in G2 phase renders the protein unable to function.
DISCUSSION
Centriole duplication is a highly orchestrated process that occurs once per cell cycle. Deregulated duplication often leads to amplification, a hallmark of cancer cells. 5 As centriole amplification is believed to be an early event in tumorigenesis, 5,7-9 it is essential to identify the factors that control the duplication process and examine their relevance to cancer development. CDK2 has emerged as a master regulator of duplication. However, much remains to be studied about how CDK2 controls this process, in part because a complete set of centrosomal CDK2 substrates have not been identified. Here, we uncovered a link between CDK2 and Cep76, a protein that limits centriole duplication to once per cell cycle, 29 and demonstrated that the latter is a bona fide substrate of the former. To our knowledge, Cep76 is the first CDK2 substrate known to negatively regulate centriole amplification, as a small handful of substrates identified to date promote duplication and amplification in a positive manner. Several centrosomal proteins, including Cep76, origin recognition complex 1, minichromosome maintenance 5, RNA-binding motif protein 14 and CDC14 are reported to suppress centriole amplification without affecting normal duplication. 29, [53] [54] [55] [56] [57] Their mechanisms of action, however, have not been fully deciphered. Although minichromosome maintenance 5 and origin recognition complex 1 associate with both cyclin E and cyclin A, only origin recognition complex 1 inhibits cyclin/CDK2 activity. CDC14 dephosphorylates certain CDK substrates and may counteract CDK-mediated phosphorylation of centrosomal substrates. 58, 59 RNA-binding motif protein 14 has no connection to CDK2; it suppresses the assembly of centriolar protein complexes that would lead to the formation of extra centrioles. Unlike the aforementioned proteins, Cep76 is a CDK2 substrate, and its phosphorylation by CDK2 is required to suppress centriole amplification. Although CDK2 can impinge on Cep76 function, the converse is not true, as Cep76 does not substantially affect the activity or localization of the kinase. Instead, our data revealed that Cep76 phosphorylation blocks Plk1 activity, thereby preventing premature centriole disengagement and amplification. Thus, the mechanism by which Cep76 suppresses centriole amplification appears to be unique.
Centriole disengagement is known to require the activities of Plk1 and the anaphase-promoting complex. 52, 60, 61 Although either activity alone is sufficient to disengage centrioles, the extent to which they contribute to this intricate process remains unclear. We showed that Cep76 can prevent centriole disengagement and amplification in S phase but not in G2 phase. Thus, it is possible that HU-induced centriole disengagement is more highly dependent on Plk1, which can be easily overcome by Cep76 expression, whereas RO 3306-and doxorubicin-induced disengagement is less dependent on Plk1. In support of this, we found that expression of a constitutively active Cep76 mutant S83EK279R, which retains the ability to block Plk1 activation at the centrosome, cannot suppress centriole amplification in RO 3306-treated cells (Supplementary Figure S10 ). Another possibility is that Cep76 could specifically function in S phase and not in G2 phase. The two possibilities are not mutually exclusive.
Our data suggest that the function of Cep76 is modulated in a temporal manner during the cell cycle by two different types of posttranslational modification. As Cep76 protein levels peak in S phase and coincide with centriole duplication, 29, 60, 61 we envision that this protein is phosphorylated and becomes activated by cyclin A/CDK2 in S phase to control the fidelity of duplication. Disruption of S83 phosphorylation, such as the phosphorylation site mutation S83A and the S83C mutation found in human cancer, compromises protein function. Once duplication is completed, Cep76 becomes acetylated at K279 in G2 phase. Acetylation of Cep76 serves to block S83 phosphorylation and to directly inhibit protein function possibly by relieving Plk1 from inhibition ( Figure 6 and Supplementary figure S10). It is uncertain how acetylation prevents protein phosphorylation. The K279Q mutant can still bind cyclin A/CDK2 (data not shown), suggesting that acetylation does not affect the interaction between the substrate and the kinase. Instead, acetylation of Cep76 may enhance its binding to a phosphatase, which can promote dephosphorylation at S83, in a manner similar to the effect of acetylation on glycogen phosphorylase phosphorylation. 62 As several phosphatases were identified in our proteomic screen for Cep76-interacting partners (data not shown), experiments are currently underway to determine if any of these could interact with Cep76.
In conclusion, we established that CDK2-mediated phosphorylation of a novel centrosomal substrate Cep76 is required to block centriole amplification in S phase. We also demonstrated the significance of a functional crosstalk between phosphorylation and acetylation. These results raise the intriguing possibility that deregulation of Cep76 may be linked to cancer risk.
MATERIALS AND METHODS
Cell culture and plasmids U2OS, Saos-2 and HEK293 cells (American Type Culture Collection, Manassas, VA, USA) were grown in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum at 37°C in a humidified 5% CO 2 atmosphere. A plasmid expressing human recombinant Flag-Cep76 protein, pCDEF3-Flag-Cep76, was described previously. 29 The following Cep76 mutations (S83C, S83A, S83E, S83AT335AS558AS615A, K279R,  K279Q, S83AK279R, S83EK279Q, S83EK279R, AXA12-14, AXA54-56,  AXA67-69, AXA106-108, AXA325-327, AXA331-333, AXA448-450, AXA533 -535 and AXA541-543) were introduced into full-length complementary DNA by using a two-step PCR mutagenesis strategy and sub-cloned into pCDEF3-Flag. All constructs were verified by DNA sequencing. Myc-cyclin A and CDK2-HA plasmids were obtained from J Archambault (Montreal, QC, Canada), and myc-Plk1-T210D was obtained from Addgene (Cambridge, MA, USA).
Antibodies
Antibodies used in this study included anti-HA (sc-7392), anti-myc (sc-40), anti-CDK2 (sc-163), anti-CDK1 (sc-954), anti-CDK4 (sc-4601), anti-CDK6 (sc-177), anti-cyclin A (sc-751), anti-cyclin E (sc-481), anti-C-Nap1 (sc-1358) (Santa Cruz, Dallas, TX, USA); anti-α-tubulin (T5168), anti-Flag (F7425), antiγ-tubulin (T3559) (Sigma, Oakville, ON, Canada); anti-acetyl lysine (#9441; Cell Signaling, Danvers, MA, USA); anti-phosphoserine (05-1000X; Millipore, Etobicoke, ON, Canada); anti-Plk1-pT210 (ab39068; Abcam, Toronto, ON, Canada) and anti-CP110 (A301-344A) and anti-Cep76 (A302-326A) (Bethyl Laboratories, Montgomery, TX, USA).
Mass spectrometric identification of Cep76 associated proteins and phosphorylation sites
To identify Cep76-interacting proteins, Flag-Cep76 was expressed in HEK293 and U2OS cells and immunoprecipitated with anti-Flag agarose beads (Sigma) for 2 h at 4°C. Bounded proteins were eluted with Flag peptide for 30 min, and the resultant eluates were precipitated with trichloroacetic acid and fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Six gel slices containing polypeptides were excised after Coomassie staining and subjected to proteolytic digestion mass spectrometric analysis. Analyses were performed at the Harvard Taplin Mass Spectrometry facility and the mass spectrometry core facility from Institut de recherches cliniques de Montréal (IRCM) by micro-capillary liquid chromatography-mass spectrometry/mass spectrometry. For the identification of phosphorylation sites, cells were treated with 100 nM calyculin A for 30 min before lysis, and the lysis buffer contained 10 mM sodium fluoride, 0.2 mM sodium orthovanadate and 50 mM β-glycerophosphate. A gel slice corresponding to Flag-Cep76 was excised. LC-MS peptide quantitation was performed by manual integration of the extracted ion chromatogram of each peptide using Qual Browser/Xcalibur version 2.2 (ThermoFisher Scientific, Waltham, MA, USA).
Immunoprecipitation, immunoblotting and immunofluorescence microscopy
Immunoprecipitation, immunoblotting and immunofluorescence were performed as described. 63, 64 Densitometric analyses were performed with the ImageJ software (v1.43 m, US National Institutes of Health, Bethesda, MD, USA) using the gel analysis and label peaks tools. ImageJ was also used to quantify the Plk1-pT210 signal at centrosomes.
Centrosome overduplication assay, cell cycle synchronization and fluorescence-activated cell sorting analysis Cells were treated with 2 mM HU (Sigma), 15 μM RO 3306 (Sigma) or 0.1 μM doxorubicin (Santa Cruz) for 48 h. The drug concentration and treatment time were optimized to minimize toxicity and to obtain the largest number of cells with overduplicated centrosomes. For cell cycle synchronization, G1, S, G2 and M phase cells were obtained by treating cells for 24 h with 0.4 mM mimosine, 2 mM HU and release for 4 h, 15 μM RO 3306 and 40 ng/ ml nocodazole, respectively. Cell cycle distribution was confirmed by fluorescence-activated cell sorting as described previously. 64 
RNA interference
Transfection of siRNAs was performed using siImporter (Millipore) as per the manufacturer's instructions. The 21-nucleotide siRNA sequence for the nonspecific control was 5′-AATTCTCCGAACGTGTCACGT-3′. The 21-nucleotide siRNA sequences for Cep76 were 5′-GAGCGTACAACAAGTA TATTT-3′ and 5′-AATCACAATCTGGCTTGAATGTT-3′ (for targeting the 3′UTR region) (Dharmacon, Ottawa, ON, Canada).
Production of recombinant proteins
Purified and active cyclin A/CDK2 and cyclin E/CDK2 were obtained from Millipore. Flag-Cep76 wild-type or mutant, or Flag-NPHP5, was expressed in U2OS cells, lysed and incubated with anti-Flag beads for 2 h. Beads were washed twice with erythrocytes lysis buffer containing 500 mM NaCl and proteins were eluted with Flag peptide. A small sample was run on a gel and Coomassie stained to assess protein purity. We determined that our Flag-Cep76 or Flag-NPHP5 protein was at least 90% pure.
In vitro binding assay
In all, 1 μg of purified Flag-Cep76 protein was mixed with 1 μg of purified cyclin A/CDK2 or cyclin E/CDK2 at 4°C for 1 h, followed by incubation with anti-Flag agarose beads at 4°C for 2 h. After extensive washing with erythrocytes lysis buffer, bound proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting.
In vitro kinase assay
The ADP-Glo kinase assay (Promega, Madison, WI, USA) was used for the in vitro kinase assay. The assay was carried out as per the manufacturer's instructions in a 96-well plate in kinase buffer (40 mM Tris pH 7.5, 20 mM MgCl 2 , 0.1% BSA) containing 100 ng of active cyclin A/CDK2 or cyclin E/ CDK2, 1 μg of purified Flag-Cep76, histone H1 or Flag-NPHP5 and 1.25 μl of 1 mM ATP (Promega). The signal was quantitated using the GloMax 96 Microplate Luminometer (Promega). For the kinase inhibition assay, histone H1 was used as a substrate for cyclin A/CDK2 and increasing amounts of purified Flag-76 mutant protein S83A or S83E were then added to the reaction.
Statistical analysis
Experiments were performed three times. Graphs were generated in Microsoft Excel. Error bars represent standard error of the mean.
